InVivo Therapeutics Holdings Corp. (NVIV): Price and Financial Metrics


InVivo Therapeutics Holdings Corp. (NVIV): $2.34

-0.04 (-1.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NVIV Stock Price Chart Interactive Chart >

Price chart for NVIV

NVIV Price/Volume Stats

Current price $2.34 52-week high $13.77
Prev. close $2.38 52-week low $1.61
Day low $2.31 Volume 16,900
Day high $2.41 Avg. volume 60,067
50-day MA $2.18 Dividend yield N/A
200-day MA $3.96 Market Cap 4.48M

InVivo Therapeutics Holdings Corp. (NVIV) Company Bio


InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 and is based in Cambridge, Massachusetts.


NVIV Latest News Stream


Event/Time News Detail
Loading, please wait...

NVIV Latest Social Stream


Loading social stream, please wait...

View Full NVIV Social Stream

Latest NVIV News From Around the Web

Below are the latest news stories about INVIVO THERAPEUTICS HOLDINGS CORP that investors may wish to consider to help them evaluate NVIV as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | November 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | November 18, 2022

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

CAMBRIDGE, Mass, October 11, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company’s common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. T

Yahoo | October 11, 2022

InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) traded at $4.05 at close of the session on Friday, 10/07/22, made a downward move of -49.25% on its previous day’s price. Looking at the stock we see that its previous close was $7.98 and the beta (5Y monthly) reads 1.29 with the day’s price range being $4.02 – $6.05. … InVivo Therapeutics Holdings Corp.’s (NASDAQ:NVIV) Stock Is Down -49.25%, But Is It Capable Of A Rally? Read More »

Stocks Register | October 10, 2022

Visa, FTX Team Up to Launch Crypto Debit Card in 40 Countries

Visa (V) stock is on the move following news that it and FTX are teaming up to bring debit cards tied to crypto accounts to more countries.

William White on InvestorPlace | October 7, 2022

Read More 'NVIV' Stories Here

NVIV Price Returns

1-mo -2.09%
3-mo 14.71%
6-mo -69.49%
1-year -74.52%
3-year -98.54%
5-year -99.98%
YTD -0.43%
2022 -79.39%
2021 -43.69%
2020 -87.99%
2019 -85.11%
2018 -92.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8028 seconds.